It's like filling in the blanks on a patient's medical puzzle using AI, so researchers don't have to run expensive lab tests for every single data type.

Strand AI's core engineering capability is a multimodal foundation model trained on large-scale, paired biological datasets spanning genomics, transcriptomics, proteomics, imaging, and spatial biology. When a pharma partner has clinical trial samples with only one or two modalities measured (e.g., H&E pathology slides and bulk RNA-seq), the model predicts the missing modalities—such as single-cell proteomics or spatial transcriptomics—with high fidelity. This dramatically reduces the cost and time of running additional wet-lab assays on every patient sample, while simultaneously enriching the dataset for downstream biomarker discovery and patient stratification. The model leverages self-supervised pretraining on unpaired data and fine-tuning on paired multimodal cohorts, using attention-based architectures that learn cross-modal biological relationships. Active learning modules further guide which samples would benefit most from actual experimental validation, optimizing the balance between computational prediction and lab confirmation.

It's like a detective who can reconstruct an entire crime scene from a single fingerprint—except the crime scene is a patient's molecular biology and the fingerprint is a routine tissue slide.

It's like hiring a tireless librarian who instantly organizes millions of messy, inconsistently labeled biology files into one perfectly standardized catalog.

One of the biggest bottlenecks in building AI-ready biological datasets is the inconsistency of metadata across institutions, studies, and data formats—gene names, tissue types, disease classifications, and assay protocols are labeled differently everywhere. Strand AI deploys a retrieval-augmented generation (RAG) pipeline powered by large language models to automatically ingest, parse, and normalize metadata from diverse sources (clinical records, genomic databases, imaging repositories, published literature). The LLM retrieves relevant ontology entries (e.g., from SNOMED, MeSH, Gene Ontology) and maps raw metadata fields to standardized terms with high accuracy, flagging ambiguous cases for human review. This pipeline also includes document management tools (visible in their open-source GitHub repos) that chunk, embed, and index research papers and clinical protocols for contextual retrieval during curation. The result is a clean, interoperable data layer that feeds directly into their foundation model training and customer-facing data products, dramatically reducing the weeks-to-months timeline traditionally required for manual data harmonization.

It's like Google Translate for biology data—except instead of converting French to English, it converts "BRCA1 mutation" labeled five different ways across ten hospitals into one universal language.

It's like using AI to find hidden patterns in patient data that tell doctors exactly which patients will respond best to a new drug.

Once Strand AI's foundation models have imputed complete multimodal profiles for patient cohorts, the enriched datasets unlock a powerful downstream capability: AI-driven biomarker discovery and patient stratification. By applying unsupervised clustering, attention-based feature attribution, and supervised outcome prediction models across the imputed multimodal data (genomics, proteomics, imaging features, clinical outcomes), Strand AI can identify molecular signatures that distinguish responders from non-responders, predict disease progression, or reveal previously unrecognized patient subgroups. These insights are packaged into a product layer that pharma partners use to design smarter clinical trials—selecting the right patients, choosing the right endpoints, and de-risking expensive late-stage studies. The multimodal nature of the imputed data is critical: biomarkers that only emerge at the intersection of, say, spatial protein expression and genomic variants would be invisible in single-modality analyses. This capability transforms Strand AI from a data infrastructure company into a strategic partner for precision medicine, directly impacting trial success rates and time-to-market for new therapeutics.

It's like Netflix recommendations, but instead of suggesting your next binge-watch, it's suggesting which patients are most likely to benefit from a new cancer drug—and it's using data the doctors didn't even know they had.